

Sherrie Bhoori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3754208/publications.pdf>

Version: 2024-02-01

44
papers

5,764
citations

218381

26
h-index

253896

43
g-index

45
all docs

45
docs citations

45
times ranked

5961
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology</i> , The, 2009, 10, 35-43.	5.1	1,920
2	Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. <i>Liver Transplantation</i> , 2011, 17, S44-S57.	1.3	471
3	Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. <i>Hepatology</i> , 2013, 57, 1826-1837.	3.6	428
4	Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. <i>Hepatology</i> , 2006, 44, 1543-1554.	3.6	347
5	Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma. <i>Transplantation</i> , 2016, 100, 116-125.	0.5	339
6	Resection of hepatocellular cancer ≤ 2 cm: Results from two Western centers. <i>Hepatology</i> , 2013, 57, 1426-1435.	3.6	326
7	Liver Transplantation for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2008, 15, 1001-1007.	0.7	249
8	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 947-956.	5.1	166
9	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. <i>American Journal of Transplantation</i> , 2016, 16, 2892-2902.	2.6	151
10	Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study. <i>Journal of Hepatology</i> , 2013, 59, 59-66.	1.8	128
11	Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1718-1738.	3.3	128
12	Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2016, 151, 846.	2.2	106
13	Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. <i>Journal of Hepatology</i> , 2018, 68, 724-732.	1.8	100
14	mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors. <i>Annals of Surgery</i> , 2020, 272, 855-862.	2.1	85
15	Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: A proof of principle. <i>Journal of Hepatology</i> , 2010, 52, 771-775.	1.8	82
16	Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 645-653.	1.4	71
17	Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.. , 2021, 9, e003311.		66
18	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	2.6	60

#	ARTICLE	IF	CITATIONS
19	Transarterial Chemoembolization for Hepatocellular Carcinoma with a New Generation of Beads: Clinicalâ€“Radiological Outcomes and Safety Profile. CardioVascular and Interventional Radiology, 2015, 38, 129-134.	0.9	59
20	Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget, 2016, 7, 72343-72355.	0.8	57
21	The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. Transplant International, 2010, 23, 712-722.	0.8	45
22	Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation, 2020, 104, 1143-1149.	0.5	41
23	Rectal hyperreactivity to distention in patients with irritable bowel syndrome: role of distention rate. Clinical Gastroenterology and Hepatology, 2004, 2, 49-56.	2.4	40
24	Role of Home Parenteral Nutrition in Chronic Radiation Enteritis. American Journal of Gastroenterology, 2006, 101, 374-379.	0.2	36
25	Current challenges in liver transplantation for hepatocellular carcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2014, 28, 867-879.	1.0	30
26	De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Managementâ€“Guidelines From the ILTS-SETH Consensus Conference. Transplantation, 2022, 106, e30-e45.	0.5	29
27	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. Liver International, 2016, 36, 1033-1042.	1.9	28
28	Intrahepatic Flow Redistribution in Patients Treated with Radioembolization. CardioVascular and Interventional Radiology, 2015, 38, 322-328.	0.9	21
29	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. Liver Transplantation, 2021, 27, 1767-1778.	1.3	19
30	Repeated transarterial chemoembolization: An overfitting effort?. Journal of Hepatology, 2015, 62, 1440-1442.	1.8	18
31	First-Line Treatment for Hepatocellular Carcinoma: Resection or Transplantation?. Transplantation Proceedings, 2007, 39, 2271-2273.	0.3	15
32	Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. BMC Cancer, 2018, 18, 715.	1.1	15
33	Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors. Transplantation, 2021, 105, 2579-2586.	0.5	13
34	Outcomes of Liver Transplant for Adults With Wilsonâ€™s Disease. Liver Transplantation, 2020, 26, 507-516.	1.3	12
35	Radioembolization of Hepatocellular Carcinoma with 90Y Glass Microspheres: No Advantage of Voxel Dosimetry with Respect to Mean Dose in Doseâ€“Response Analysis with Two Radiological Methods. Cancers, 2022, 14, 959.	1.7	11
36	Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from preâ€“to postâ€“liver transplant: a realâ€“life strategy. Liver International, 2017, 37, 678-683.	1.9	10

#	ARTICLE	IF	CITATIONS
37	Alpha-fetoprotein in liver transplantation for hepatocellular carcinoma: The lower, the better. <i>Hepatology</i> , 2018, 68, 775-777.	3.6	8
38	Thrombosis after liver transplantation for hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0186699.	1.1	8
39	Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. <i>Transplant International</i> , 2015, 28, 1055-1065.	0.8	7
40	Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2017, 67, 415-417.	1.8	7
41	Endoscopic ultrasound-guided fine needle aspiration of splenic vein thrombosis: a novel approach to the portal venous system. <i>Endoscopy</i> , 2016, 48, E40-E41.	1.0	4
42	HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post-hoc analysis. <i>Transplant International</i> , 2020, 33, 917-924.	0.8	4
43	Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 2187-2193.	1.9	2
44	Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2022, 6, e2100472.	1.5	2